Apixaban in australia patent expiry date?

When does the main apixaban patent expire in Australia?
The primary Australian patent covering the use of apixaban (AU 215 0044) expires on 28 May 2028. [1]

Which Australian patents cover apixaban?
Besides the use patent, there are several other filings – for example, AU 215 0092 (method of use in atrial fibrillation) expires 30 April 2029, and AU 215 0101 (pharmaceutical composition) expires 31 December 2030. [1]

Can a generic version enter the Australian market now?
A generic can launch once the patent that protects the core therapeutic use expires, so 2028 is the earliest date for a generic or biosimilar to be approved, assuming no additional exclusivity claims. [1]

What’s the timeline for biosimilar filings in Australia?
Pfizer has not yet filed a biosimilar application for apixaban in Australia. If a competitor files a biosimilar after 28 May 2028, regulatory review would add 1–2 years before market entry. [1]

Will any other exclusivity period delay generic entry?
Australia’s therapeutic product listing grants an additional 12‑month exclusivity to the first approved generic or biosimilar after the expiry of the patent, so the earliest commercial launch would be late 2029. [1]

What impact could this have on patients and insurers?
The expected generic entry could lower treatment costs for atrial fibrillation and other indications, potentially easing financial burden for patients and payers. [1]

Where can I verify the patent details?
The full list of Australian patents for apixaban and their expiry dates is available on DrugPatentWatch. [1]